Literature DB >> 20878139

[Functioning of the anaesthetic conserving device: aspects to consider for use in inhalational sedation].

A Meiser1, M Bellgardt, H Vogelsang, C Sirtl, T Weber.   

Abstract

The new anaesthetic conserving device (ACD) allows the use of isoflurane and sevoflurane without classical anaesthesia workstations. Volatile anaesthetic exhaled by the patient is absorbed by a reflector and released to the patient during the next inspiration. Liquid anaesthetic is delivered via a syringe pump. Currently the use of the ACD is spreading among European intensive care units (ICU). This article focuses on the functioning of the device and on particularities which are important to consider. The ACD constantly reflects 90% of the exhaled anaesthetic back to the patient, but if one exhaled breath contains more than 10 ml of anaesthetic vapour (e.g. >1 vol% in 1,000 ml), the capacity of the reflector will be exceeded and relatively more anaesthetic will be lost to the patient. This spill over decreases efficiency but it also contributes to safety as very high concentrations are averted. Compared to classical anaesthesia systems the ACD used in conjunction with ICU ventilators offers advantages in the ICU setting: investment costs are low, carbon dioxide absorbent is not needed, breathing comfort is higher, anaesthetic consumption is low (equal to an anaesthesia circuit with a fresh gas flow of approximately 1 l/min) and anaesthetic concentrations can be controlled very quickly (increased by small boluses and decreased by removal of the ACD). On the other hand, case costs are higher (single patient use) and a dead space of 100 ml is added. There are pitfalls: by a process called auto-pumping, expansion of bubbles inside the syringe may lead to uncontrolled anaesthetic delivery. Auto-pumping is provoked by high positioning of the syringe pump, heat and prior cooling of the liquid anaesthetic. Inherent to the device is an early inspiratory concentration peak and an end-inspiratory dip which may mislead commonly used gas monitors. Workplace concentrations can be minimized by proper handling, a sufficient turnover of room air is important and gas from the expiration port of the ventilator should be scavenged. Inhalational compared to intravenous ICU sedation offers the advantages of better control of the sedation level, online drug monitoring, no accumulation in patients with renal or hepatic insufficiency and bronchodilation. With a lowered opioid dose spontaneous breathing and intestinal motility are well preserved. A clinical algorithm for the care of patients with respiratory insufficiency including inhalational sedation is proposed. Inhalational sedation with isoflurane has been widely used for more than 20 years in many countries and even for periods of up to several weeks. In the German S3 guidelines for the management of analgesia, sedation and delirium in intensive care (Martin et al. 2010), inhalational sedation is mentioned as an alternative sedation method for patients ventilated via an endotracheal tube or a tracheal cannula. Nevertheless, isoflurane is not officially licensed for ICU sedation and its use is under the responsibility of the prescribing physician.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878139     DOI: 10.1007/s00101-010-1779-6

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  31 in total

1.  Excess delivery of isoflurane liquid from a syringe driver.

Authors:  J D R Henning; R Bateman
Journal:  Anaesthesia       Date:  2004-12       Impact factor: 6.955

2.  Use of sevoflurane sedation by the AnaConDa device as an adjunct to extubation in a pediatric burn patient.

Authors:  C Jung; M Granados; P Marsol; I Murat; O Gall
Journal:  Burns       Date:  2007-02-28       Impact factor: 2.744

3.  Use of the AnaConDa anaesthetic delivery system to treat life-threatening asthma.

Authors:  H Thomson; N J Harper; A Parkes
Journal:  Anaesthesia       Date:  2007-03       Impact factor: 6.955

4.  Population pharmacokinetics of sevoflurane in conjunction with the AnaConDa: toward target-controlled infusion of volatiles into the breathing system.

Authors:  M Enlund; D Kietzmann; T Bouillon; K Züchner; I Meineke
Journal:  Acta Anaesthesiol Scand       Date:  2008-04       Impact factor: 2.105

5.  The predictive performance of a pharmacokinetic model for manually adjusted infusion of liquid sevofluorane for use with the Anesthetic-Conserving Device (AnaConDa): a clinical study.

Authors:  Javier F Belda; Marina Soro; Rafael Badenes; Andreas Meiser; María Luisa García; Gerardo Aguilar; Francisco J Martí
Journal:  Anesth Analg       Date:  2008-04       Impact factor: 5.108

6.  Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device.

Authors:  Peter V Sackey; Claes-Roland Martling; Fredrik Granath; Peter J Radell
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

7.  Technical performance and reflection capacity of the anaesthetic conserving device--a bench study with isoflurane and sevoflurane.

Authors:  Andreas Meiser; Martin Bellgardt; Javier Belda; Kerstin Röhm; Heinz Laubenthal; Clemens Sirtl
Journal:  J Clin Monit Comput       Date:  2009-02-03       Impact factor: 2.502

8.  Short-term sevoflurane sedation using the Anaesthetic Conserving Device after cardiothoracic surgery.

Authors:  Kerstin D Röhm; Michael W Wolf; Thilo Schöllhorn; Alexander Schellhaass; Joachim Boldt; Swen N Piper
Journal:  Intensive Care Med       Date:  2008-05-24       Impact factor: 17.440

9.  Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial.

Authors:  Timothy D Girard; John P Kress; Barry D Fuchs; Jason W W Thomason; William D Schweickert; Brenda T Pun; Darren B Taichman; Jan G Dunn; Anne S Pohlman; Paul A Kinniry; James C Jackson; Angelo E Canonico; Richard W Light; Ayumi K Shintani; Jennifer L Thompson; Sharon M Gordon; Jesse B Hall; Robert S Dittus; Gordon R Bernard; E Wesley Ely
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321

10.  Isoflurane therapy for status asthmaticus in children and adults.

Authors:  R G Johnston; T W Noseworthy; E G Friesen; H A Yule; A Shustack
Journal:  Chest       Date:  1990-03       Impact factor: 9.410

View more
  6 in total

1.  Uncontrolled delivery of liquid volatile anaesthetic when using the anaesthetic conserving device.

Authors:  Igor Karnjuš; Dušan Mekiš; Miljenko Križmarić
Journal:  J Clin Monit Comput       Date:  2017-05-31       Impact factor: 2.502

Review 2.  [New technical developments for inhaled sedation].

Authors:  A Meiser; H Bomberg; T Volk; H V Groesdonk
Journal:  Anaesthesist       Date:  2017-04       Impact factor: 1.041

Review 3.  Efficient application of volatile anaesthetics: total rebreathing or specific reflection?

Authors:  Hagen Bomberg; Thomas Volk; Heinrich V Groesdonk; Andreas Meiser
Journal:  J Clin Monit Comput       Date:  2018-01-04       Impact factor: 2.502

4.  A novel device for target controlled administration and reflection of desflurane--the Mirus™.

Authors:  H Bomberg; M Glas; V H Groesdonk; M Bellgardt; J Schwarz; T Volk; A Meiser
Journal:  Anaesthesia       Date:  2014-07-09       Impact factor: 6.955

5.  Anesthetic gas consumption with target-controlled administration versus a semi-closed circle system with automatic end-tidal concentration control in an artificial lung model.

Authors:  Martin Bellgardt; Vladimir Vinnikov; Adrian Iustin Georgevici; Livia Procopiuc; Thomas Peter Weber; Andreas Meiser; Jennifer Herzog-Niescery; Dominik Drees
Journal:  Med Gas Res       Date:  2022 Oct-Dec

6.  Efficiency and safety of inhalative sedation with sevoflurane in comparison to an intravenous sedation concept with propofol in intensive care patients: study protocol for a randomized controlled trial.

Authors:  Jens Soukup; Antje Selle; Andreas Wienke; Jörg Steighardt; Nana-Maria Wagner; Patrick Kellner
Journal:  Trials       Date:  2012-08-10       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.